There is a conversation happening in pharma boardrooms right now, and it is focused on the wrong question.
Which foundation model. Which vendor. Which benchmark. Which feature set. None of these are the things that will separate the companies getting value from AI in 2026 from the companies still running pilots three years from now.
The Quiet Shift to Architecture
The companies that have already figured this out have shifted their investment away from the model layer entirely. The model is a component, swapped when better options appear. The architecture around it is the durable investment.
Governance scaffolding. Semantic grounding. Explainability design. Ontology layers. Data contracts. MLR workflows that can withstand regulatory audit. HCP data models that actually link across CRM, claims, and engagement signals. None of these can be procured. All of them take 18 to 36 months of unglamorous work to build.
Why Architecture Work Is Underfunded
The honest reason most pharma organizations skip this work is not that they do not understand its value. It is that foundation work fails every conventional ROI test. The payoff is contingent on a future deployment the board has not approved yet. You are asking finance to fund insurance against a risk the business case says does not exist.
Foundation work is almost designed to fail standard business cases. Its value is contingent on AI deployments that have not happened. Board approval processes reward investments with direct attributable outcomes. Foundation work fails that test by definition.
The Three Funding Patterns That Actually Work
The companies funding architecture anyway have one of three patterns.
The first is reclassification. Foundation spend is moved out of business unit P and L into enterprise IT or CTO budget. This breaks the attribution tie but requires a CEO with the air cover to push it.
The second is disguise. Foundation work is tied to a concrete near term use case that pays for itself, and the project budget is used to build reusable capability as a by product. The discipline is insisting on reusable architecture even when the project sponsor does not care about it.
The third is failure recovery. A high profile AI program stalls at pilot, the post mortem reveals foundation gaps, and budget gets reallocated that nobody would have approved cleanly. This is the most common path. It is also the most expensive.
Most companies are still on the third pattern.
What This Looks Like at Companies Doing It Right
At the Pistoia Alliance Spring Conference in London, four major pharma companies presented their AI architectures, and they all looked structurally similar. AstraZeneca's agent architecture for scientist queries grounded on FAIR R and D data. AbbVie's governance and permissions layer with explainability first retrieval. IBM Science Zero's orchestrator and specialized agents for regulatory writing. Roche's reference model built on Basic Formal Ontology and the Pistoia Alliance Pharma General Ontology.
Four organizations, four problems, one shared characteristic. The model itself is a component, selected for fit and swapped when better options appear. The architecture is the durable investment.
The Same Pattern on the Commercial Side
The commercial side of pharma is seeing the exact same pattern. Every brand team is asking which vendor has the best generative AI for HCP content. Almost nobody is asking whether their segmentation layer, content governance, MLR workflow, and HCP data model can actually support production AI at scale.
Without those, the model choice is irrelevant. Swap vendors next year and the same pilots will stall.
The Prediction
Frontier models will become commodities. The capability gap between leading options narrows every quarter. Any model based advantage is transient by definition.
The companies that built their semantic layer and governance posture in 2023 will look like they suddenly pulled ahead in 2027. The reality is they did the unglamorous work three years before everyone else noticed it mattered.
The question that will matter in 2027 is not which model your company chose in 2026. It is whether you used 2026 to build the architecture needed to make AI defensible in a regulated industry.
